Mct11 antibodies to treat t cell functional exhaustion and enhance cancer immunotherapy
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsGreg M. Delgoffe, Ronal Peralta
Life of this patent
Estimating the term…
Abstract
Monoclonal antibodies and antigen binding fragments that specifically bind MCT11 are provided. Also disclosed are nucleic acid molecules encoding the antibody, vectors including these nucleic acid molecules, and host cells transfected with these vectors. Methods of using MCT11 specific antibodies to treat cancer, inhibit or treat T cell exhaustion, and/or enhance immunotherapy, are also provided.
Claims31
A monoclonal antibody that specifically binds monocarboxylate transporter 11 (MCT11), comprising a variable heavy (VH) domain and a variable light (VL) domain, wherein:
- the VH domain comprises the heavy chain complementarity determining region (CDR) 1, a CDR2, and a CDR3 of SEQ ID NO:
- 1, and
- the VL domain comprises the light chain complementarity determining region (CDR)1, a CDR2, and a CDR3 of SEQ ID NO:
- 5.
(canceled)
8-10. (canceled)
(canceled)
(canceled)
(canceled)
18-19. (canceled)
A method for reducing T cell exhaustion, reducing lactic acid uptake by an exhausted T cell, increasing effector function of a T cell, or combinations thereof, comprising:
- (a) contacting the exhausted T cell or T cell with an effective amount of an antibody specific for monocarboxylate transporter 11 (MCT11);
- or
- (b) expressing a nucleic acid molecule or a vector encoding the antibody specific for MCT11 in the exhausted T cell or T cell;
- thereby reducing T cell exhaustion, reducing lactic acid uptake by an exhausted T cell, increasing effector function of a T cell, or combinations thereof.
25-28. (canceled)
A method for treating cancer or a tumor, or increasing an immune response in a subject, comprising administering to the subject a therapeutically effective amount of an antibody specific for monocarboxylate transporter 11 (MCT11),
- thereby treating the cancer or tumor, or increasing the immune response.
(canceled)
33-35. (canceled)
37-43. (canceled)
A method of increasing an immune response in a subject being treated with an antibody specific for monocarboxylate transporter 11 (MCT11), comprising administering an immunotherapy to the subject, optionally wherein the subject has cancer.
45-55. (canceled)
Dependencies are inferred from the claim text.